CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)

May 10, 2019 admin CEO Interview, Healthcare Comments Off on CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)
Nader Pourhassan, Ph.D

 

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

 

 

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, providing an update on the company’s drug development pipeline targeting HIV and cancers, based on CytoDyn’s Leronlimab/PRO 140 platform.

CytoDyn’s combination therapy for HIV is expected to receive FDA approval in 2019, and potentially generating revenues by early 2020. Especially compelling is the possibility of CytoDyn’s HIV monotherapy which could get potential FDA approval the following year. CytoDyn’s monotherapy is a potential “game changer” in HIV treatment, requiring only a once-weekly injection which can be self-administered.  

Dr. Pourhassan also provides an update on CytoDyn’s portfolio of potential cancer therapies which are now entering clinical trials. 

Investor Presentation

Cytodyn presentation




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

January 13, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

VANCOUVER, Washington, Jan. 13, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 admin Healthcare, Newsmakers Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]

Healthcare

Hoth Therapeutics (NASDAQ: HOTH) to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

September 6, 2019 admin Healthcare, Newsmakers Comments Off on Hoth Therapeutics (NASDAQ: HOTH) to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

NEW YORK, Sept. 6, 2019  — Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, […]